Publications by authors named "Mark A Currier"

Claim this Profile
D
Development of VNX-101, an adeno-associated virus with less immunogenicity and efficient long-term expression of a CD19 T cell engager.
Mark A Currier, Allen Reha, Brian Hutzen, Pin-Yi Wang, Chun-Yu Chen

Mol Ther Methods Clin Dev· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trabectedin promotes oncolytic virus antitumor efficacy, viral gene expression, and immune effector function in models of bone sarcoma.
Emily M Ringwalt, Mark A Currier, Andrea M Glaspell, Chun-Yu Chen, Matthew V Cannon

Mol Ther Oncol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Corrigendum: Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.
Siddhi N Paudel, Brian J Hutzen, Katherine E Miller, Elizabeth A R Garfinkle, Chun-Yu Chen, Mark A Currier

Front Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelomodulatory treatments augment the therapeutic benefit of oncolytic viroimmunotherapy in murine models of malignant peripheral nerve sheath tumors.
Siddhi N Paudel, Brian J Hutzen, Katherine E Miller, Elizabeth A R Garfinkle, Chun-Yu Chen, Mark A Currier

Front Immunol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Trabectedin Enhances Oncolytic Virotherapy by Reducing Barriers to Virus Spread and Cytotoxic Immunity in Preclinical Pediatric Bone Sarcoma.
Emily M Ringwalt, Mark A Currier, Andrea M Glaspell, Chun-Yu Chen, Matthew V Cannon

bioRxiv· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opportunities and challenges of combining adoptive cellular therapy with oncolytic virotherapy.
Joseph A Mamola, Chun-Yu Chen, Mark A Currier, Kevin Cassady, Dean A Lee

Mol Ther Oncolytics· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leveraging gene therapy to achieve long-term continuous or controllable expression of biotherapeutics.
Timothy P Cripe, Brian Hutzen, Mark A Currier, Chun-Yu Chen, Andrea M Glaspell

Sci Adv· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endogenous retrovirus envelope as a tumor-associated immunotherapeutic target in murine osteosarcoma.
Mary Frances Wedekind, Katherine E Miller, Chun-Yu Chen, Pin-Yi Wang, Brian J Hutzen, Mark A Currier

iScience· July 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Cationic Nanomicellar Complex of the Quaternary Amphiphilic Amine RC16+ with Fenretinide as a New Multitasking System for Antitumor Therapy.
Isabella Orienti, Timothy P Cripe, Mark A Currier, Cristina Cavallari, Gabriella Teti

Curr Drug Deliv· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial.
Keri A Streby, Mark A Currier, Melinda Triplet, Kristy Ott, Devon J Dishman

Mol Ther· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment.
Nicholas L Denton, Chun-Yu Chen, Brian Hutzen, Mark A Currier, Thomas Scott

Mol Ther Oncolytics· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of Cancer-Targeted Tropomyosin Inhibitors and Their Synergy with Microtubule Drugs.
Mark A Currier, Justine R Stehn, Ashleigh Swain, Duo Chen, Jeff Hook

Mol Cancer Ther· August 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Intratumoral Injection of HSV1716, an Oncolytic Herpes Virus, Is Safe and Shows Evidence of Immune Response and Viral Replication in Young Cancer Patients.
Keri A Streby, James I Geller, Mark A Currier, Patrick S Warren, John M Racadio

Clin Cancer Res· July 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aurora A kinase inhibition enhances oncolytic herpes virotherapy through cytotoxic synergy and innate cellular immune modulation.
Mark A Currier, Les Sprague, Tilat A Rizvi, Brooke Nartker, Chun-Yu Chen

Oncotarget· March 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preparation and Evaluation of a Novel Class of Amphiphilic Amines as Antitumor Agents and Nanocarriers for Bioactive Molecules.
Isabella Orienti, Mirella Falconi, Gabriella Teti, Mark A Currier, Jiang Wang

Pharm Res· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity.
Jennifer L Leddon, Chun-Yu Chen, Mark A Currier, Pin-Yi Wang, Francesca A Jung

Mol Ther Oncolytics· April 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 1 study of intratumoral Pexa-Vec (JX-594), an oncolytic and immunotherapeutic vaccinia virus, in pediatric cancer patients.
Timothy P Cripe, Minhtran C Ngo, James I Geller, Chrystal U Louis, Mark A Currier

Mol Ther· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
VEGF blockade enables oncolytic cancer virotherapy in part by modulating intratumoral myeloid cells.
Mark A Currier, Francis K Eshun, Allyson Sholl, Artur Chernoguz, Kelly Crawford

Mol Ther· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer screening by systemic administration of a gene delivery vector encoding tumor-selective secretable biomarker expression.
Andrew W Browne, Jennifer L Leddon, Mark A Currier, Jon P Williams, Jason S Frischer

PLoS One· May 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overexpression of the cellular DEK protein promotes epithelial transformation in vitro and in vivo.
Trisha M Wise-Draper, Rachael A Mintz-Cole, Teresa A Morris, David S Simpson, Kathryn A Wikenheiser-Brokamp, Mark A Currier

Cancer Res· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of the oncolytic herpes simplex virus rRp450 alone and combined with cyclophosphamide.
Mark A Currier, Rebecca A Gillespie, Nancy M Sawtell, Yonatan Y Mahller, Greg Stroup

Mol Ther· May 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic HSV and erlotinib inhibit tumor growth and angiogenesis in a novel malignant peripheral nerve sheath tumor xenograft model.
Yonatan Y Mahller, Sachin S Vaikunth, Mark A Currier, Shyra J Miller, Maria C Ripberger

Mol Ther· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Oncolytic herpes simplex virus mutants are more efficacious than wild-type adenovirus Type 5 for the treatment of high-risk neuroblastomas in preclinical models.
Nehal S Parikh, Mark A Currier, Yonatan Y Mahller, Lisa C Adams, Betsy Di Pasquale

Pediatr Blood Cancer· May 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
W
Widespread intratumoral virus distribution with fractionated injection enables local control of large human rhabdomyosarcoma xenografts by oncolytic herpes simplex viruses.
Mark A Currier, Lisa C Adams, Yonatan Y Mahller, Timothy P Cripe

Cancer Gene Ther· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Ewing sarcoma family of tumors express adenovirus receptors and are susceptible to adenovirus-mediated oncolysis.
Anna M Rice, Mark A Currier, Lisa C Adams, Neeti S Bharatan, Margaret H Collins

J Pediatr Hematol Oncol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis